Efficacy and safety of switching from sitagliptin to liraglutide in subjects with type 2 diabetes (LIRA-SWITCH): a randomized, double-blind, double-dummy, active-controlled 26-week trial

What Was Tested

Researchers studied Liraglutide in this randomized controlled trial publication.

Who Took Part

By PubMed's age tags, the people studied were adults, middle-aged adults, older adults and people over 80, both men and women.

How the Study Was Run

The researchers set it up as a randomized, double-blind and multicenter study.

The participants were allocated by chance, so the Liraglutide group and the comparison group should start out alike.

Neither the participants nor the staff measuring them knew who was on Liraglutide, so expectations could not easily colour the readings.

More than one site took part, so the participants came from several places.

A randomized, multicentre, double-blind, double-dummy, active-controlled trial across 86 office- or hospital-based sites in North America, Europe and Asia.

The primary endpoint was change in HbA1c from baseline to week 26.

Change in body weight was a confirmatory secondary endpoint.

What Was Measured

The subject headings attached to it are Asia, Blood Glucose, Diabetes Mellitus, Type 2, Drug Substitution, Europe, Glycated Hemoglobin and Hypoglycemia.

The authors tagged it with the keywords GLP-1 receptor agonist, liraglutide, sitagliptin and type 2 diabetes.

What This Means in Plain Language

The paper is a randomized, double-blind and multicenter study of Liraglutide.

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2016 (Diabetes, obesity & metabolism), a journal based in England.

More context: the Liraglutide compound page, all human trials.